PCR in Screening and Diagnostics: Market Developments, Growth Areas and Opportunities

News provided by

Jun 04, 2013, 12:11 ET

NEW YORK, June 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PCR in Screening and Diagnostics: Market Developments, Growth Areas and Opportunities

http://www.reportlinker.com/p01211169/PCR-in-Screening-and-Diagnostics-Market-Developments-Growth-Areas-and-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Background

PCR is used in a wide variety of molecular biology applications, including sequencing, genetic fingerprinting, cloning, disease research, diagnostics, drug discovery, disease biomarkers and forensics. Today, this technique continues to grow and some estimates suggest that by 2015 global markets for this technique will exceed $27 billion. Biopharm Reports has carried out a market study of the use of PCR in screening and diagnostics, involving the participation of 173 end-users and decision-makers in more than 50 countries. This study was carried out to investigate market developments, and to identify new insights and opportunities to developers and vendors in this field.

This study focused in particular on current and future techniques and applications, end-users' plans for using PCR in screening and diagnostics over the next three years, as well as preferred products, purchasing and new developments. Other market areas included new and emerging applications, end-users' principal PCR systems and their strengths and weaknesses, current and future budgets, budget breakdown, consumables, challenges, innovation, software and sample preparation.

Overview

• Current PCR techniques: Current use of more than 40 PCR techniques in screening or diagnostics by end-users, each ranked according to their competitive position. PCR techniques considered include Allele Specific PCR, Arbitrarily Primed PCR (APPCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Bead Emulsion Amplification PCR (BEA), Classical PCR, Colony PCR, Degenerate Oligonucleotide PCR (DOPPCR), Digital PCR (dPCR), Helicase Dependent Amplification (HDA), Hot start PCR, Hyper PCR, Immunocapture PCR, In Silico PCR, Inter Sequence Specific PCR (ISSR), Inverse PCR, Ligation Mediated PCR, Long PCR, Loop Mediated Isothermal Amplification (LAMP), Methylation Specific PCR (MSP), Miniprimer PCR, Multiplex Ligation Dependent Probe Amplification (MLPA), Multiplex PCR, Nested PCR, Overlap Extension PCR ( Splicing by overlap extension, SOE), PANAC (Single Reaction Real Time PCR), PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCRRFLP), Quantitative PCR (qPCR), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Reverse Transcription PCR (RTPCR), Single Molecule PCR, Single Specific Primer Polymerase, Chain Reaction (SSPPCR), Solid Phase PCR, Stem loop RT PCR, Stepdown PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCRTTGE), Thermal Asymmetric Interlaced PCR (TAILPCR), Touchdown PCR, Universal Fast Walking or other.
• Future PCR techniques: Future anticipated use of more than 40 PCR techniques in screening or diagnostics by end-users over the next three years, each ranked according to their competitive position. PCR techniques considered include Allele Specific PCR, Arbitrarily Primed PCR (APPCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Bead Emulsion Amplification PCR (BEA), Classical PCR, Colony PCR, Degenerate Oligonucleotide PCR (DOPPCR), Digital PCR (dPCR), Helicase Dependent Amplification (HDA), Hot start PCR, Hyper PCR, Immunocapture PCR, In Silico PCR, Inter Sequence Specific PCR (ISSR), Inverse PCR, Ligation Mediated PCR, Long PCR, Loop Mediated Isothermal Amplification (LAMP), Methylation Specific PCR (MSP), Miniprimer PCR, Multiplex Ligation Dependent Probe Amplification (MLPA), Multiplex PCR, Nested PCR, Overlap Extension PCR ( Splicing by overlap extension, SOE), PANAC (Single Reaction Real Time PCR), PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCRRFLP), Quantitative PCR (qPCR), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Reverse Transcription PCR (RTPCR), Single Molecule PCR, Single Specific Primer Polymerase, Chain Reaction (SSPPCR), Solid Phase PCR, Stem loop RT PCR, Stepdown PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCRTTGE), Thermal Asymmetric Interlaced PCR (TAILPCR), Touchdown PCR, Universal Fast Walking or other.
• Current PCR applications: Current use of 15 PCR applications in screening or diagnostics by end-users, each ranked according to their competitive position.
Application considered were allele size detection for human ID STR typing, bacterial tipification (REPPCR), cell-free DNA mutations, cloning, commensal bacteria detection / quantification, community profiling, detection of antimicrobial resistance genes, detection of specific microbial 16S rRNA genes, diagnostics, drug treatment dosage prediction, drug treatment type prediction, fungal species detection, gene expression (mRNA), gene mutations and alterations, generating genetic probes, genetic mapping, genetic material amplification, sequencing, haplotypes, immunocapture PCR mediated virion detection, microbial populations, MicroRNA quantification, pathogen detection/identification, quantitative analysis of gene abundance, site-directed mutagenesis, tissue typing or other.
• Future PCR applications: Application considered were allele size detection for human ID STR typing, bacterial tipification (REPPCR), cell-free DNA mutations, cloning, commensal bacteria detection / quantification, community profiling, detection of antimicrobial resistance genes, detection of specific microbial 16S rRNA genes, diagnostics, drug treatment dosage prediction, drug treatment type prediction, fungal species detection, gene expression (mRNA), gene mutations and alterations, generating genetic probes, genetic mapping, genetic material amplification, sequencing, haplotypes, immunocapture PCR mediated virion detection, microbial populations, MicroRNA quantification, pathogen detection/identification, quantitative analysis of gene abundance, site-directed mutagenesis, tissue typing or other.
• Biomarker identity: The identities of the main biomarkers investigated using PCR.
• Biomarker types: The main biomarker types investigated using PCR, including gene variations (mutations/polymorphisms), DNA methylation, gene copy number, gene expression, SNPs, mRNA, MicroRNA, alternative spliced variants or other.
• Biomarker utility: The main clinical utilities of biomarkers investigated using PCR, including disease prognosis, disease susceptibility or risk, disease stage or severity, drug type therapy decision-making, drug type therapy dose, drug discovery, early detection of disease, clinical trial endpoint, guiding treatment, response to therapy, safety or toxicity factors or other areas.
• Current company suppliers: End-users' preferred current company suppliers for their PCR, including Abbott, Agilent, Applied Biosystems, Becton Dickinson, Bioline, Biometra, Biorad, Biotium, Biozyme, Cepheid, Eppendorf, ESCO, Euroclone, Eurogentec, Fermentas, Finnzymes, Fluidigm, GE Healthcare, Genework, Hain Life sciences, Idaho, Integrated Data Technologies, Invitrogen, Kapa Biosystems, Life Technologies, Luminex, Machery Nagel, MJ Research, New England BioLabs, Perkin Elmer, Promega, Qiagen, Quanta Bioscience, Roche, SensoQuest, Siemens, Sigma Genosys, Stratagene, Takara, Thermofisher or others.
• Future company suppliers: End-user's anticipated preferred company suppliers for their PCR over the next three years, including Abbott, Agilent, Applied Biosystems, Becton Dickinson, Bioline, Biometra, Biorad, Biotium, Biozyme, Cepheid, Eppendorf, ESCO, Euroclone, Eurogentec, Fermentas, Finnzymes, Fluidigm, GE Healthcare, Genework, Hain Life sciences, Idaho, Integrated Data Technologies, Invitrogen, Kapa Biosystems, Life Technologies, Luminex, Machery Nagel, MJ Research, New England BioLabs, Perkin Elmer, Promega, Qiagen, Quanta Bioscience, Roche, SensoQuest, Siemens, Sigma Genosys, Stratagene, Takara, Thermofisher or others.
• Preferred instrument: End-users preferred PCR instrument (from their preferred supplier) in the PCR field.
• Strengths: The strengths of end-user's preferred instrument in the PCR field (how is it meeting their needs in this area).
• Weaknesses: The weaknesses of end-users preferred instrument in the PCR field (how is it failing to meet their needs in this area).
• Bioinformatics software: End-users preferred bioinformatics software in the PCR field.
• Required innovations: End-user's views (rated on a scale of 1-10) on the PCR areas where innovations is most required. Innovation areas considered were sample preparation, ancillary techniques, PCR (qualitative) selectivity, PCR (quantitative) sensitivity, PCR reproducibility, PCR qualitative/quantitative capability, PCR robustness (ruggedness), detection methods, automation, speed or sample throughput, specialist data control systems, specialist bioinformatics systems or other.
• Samples: End-user's main samples analysed using PCR, including animal tissues, cell isolates, cells cerebrospinal fluid, genetic material, human tissues, In-vitro biological solutions, microbiological materials, plasma, saliva, serum, urine, whole blood or other.
• Sample preparation: End-user's preferred sample preparation technique.
• Recent Innovation: End-user's views on the most important PCR innovations in their field over the last three years.
• Financial Budget: End-user's annual financial budgets relating to their use of PCR in screening and diagnostics.
• Cost per sample: End-users average costs per sample, using PCR in screening and diagnostics.
• Current Budget breakdown: End user's current budget breakdown for the use of PCR in screening and diagnostics, relating to reagents and consumables, system control (data handling) software, data analysis (offline) software, PCR instruments, sample preparation and related instrumentation, ancillary systems/instrumentation, general overheads, instrument servicing/repair, staff salaries and other areas.
• Future Budget breakdown: End user's anticipated future budget breakdown for the use of PCR in screening and diagnostics, relating to reagents and consumables, system control (data handling) software, data analysis (offline) software, PCR instruments, sample preparation and related instrumentation, ancillary systems/instrumentation, general overheads, instrument servicing/repair, staff salaries and other areas.
• Overall budget: End-user's estimates of by how much they anticipate their overall annual financial budget for the use of PCR in screening and diagnostics will change, either increase or decrease, over the next three years.
• Consumables: End-users top three consumables in terms of overall costs, that are directly associated with their PCR work in screening and diagnostics.
• PCR activities: End-user's PCR activities in screening and diagnostics, relating to the running of routine PCR tests for clinical decision-making, the development or validation of PCR tests and the qualitative discovery of disease biomarkers using PCR.
• Organisation types: Organisation types in this study included universities, research Institutes, small companies, medium sized companies, large international company, clinics, hospitals, government organisations, veterinary organisation and others.
• Fields: Fields types of participants in this study included biotechnology, clinical, hospital, government, healthcare, pharmaceuticals, research institute, university or other.
• Therapeutic Areas: End-users' DNA sequencing activities in terms of their general therapeutic area, including arthritis, autoimmune diseases, done metabolism, cancer, cardiovascular, central nervous system, endocrine, gastrointestinal, genito-urinary system, haematology, infections,
inflammation, metabolic disorders, musculoskeletal disorders, nutrition, obstetrics and gynaecology, ophthalmology, pain, respiratory, skin or other.
• Purpose: End-users' underlying reasons for using PCR in screening or diagnostics across 12 areas, namely clinical research, routine diagnostics, routine screening, clinical trials, treatment decisions, treatment monitoring, diagnostics research, disease research, drug R&D, drug targets, pathology, toxicology or other.

Executive Summary

Chapter 1 Introduction

Chapter 2 Study Participants

2.1 This Chapter
2.2 Countries
2.3 Regions
2.4 Organisation Types
2.5 Fields
2.6 PCR Activities
2.7 Participants
2.8 Discussion
Figure 2.1 Countries of individuals who participated in PCR 2013 CLIN
Figure 2.2 Global regions of individuals who participated in PCR 2013 CLIN.
Figure 2.3 Organisation types of individuals who participated in PCR 2013 CLIN
Figure 2.4 Fields of individuals who participated in PCR 2013 CLIN
Table 2.1 Countries of individuals who participated in PCR 2013 CLIN
Table 2.2 Global regions of individuals who participated in PCR 2013 CLIN
Table 2.3 Organisation types of individuals who participated in PCR 2013 CLIN

Chapter 3 PCR Techniques

3.1 This Chapter
3.2 Current Techniques
3.3 Future Techniques
3.4 Discussion
Figure 3.1 Top ten currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
Table 3.1 Currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
Figure 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
Table 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
Figure 3.3 Top ten PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 3.3 PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Figure 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated PCR 2013 CLIN

Chapter 4 PCR Applications

4.1 This Chapter
4.2 Current Applications
4.3 Future Applications
4.4 Discussion
Figure 4.1 Top ten currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
Table 4.1 Currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
Figure 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
Table 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
Figure 4.3 Top ten PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 4.3 PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Figure 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN

Chapter 5 Companies

5.1 This Chapter
5.2 Current Companies
5.3 Future Companies
5.4 Discussion
Figure 5.1 Top ten PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
Table 5.1 PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
Figure 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
Table 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
Figure 5.3 Top ten PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 5.3 PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Figure 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN

Chapter 6 Preferred Companies and Products

6.1 This Chapter
6.2 Preferred Companies
6.3 Preferred products
6.4 Strengths
6.5 Weaknesses
6.6 Discussion
Figure 6.1 Top ten preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.1 Preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.3 Top ten preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.3 Preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.4 Other preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.4 Other Top preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.5 Top ten strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.5 Strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.7 Top ten weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.7 Weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN

Chapter 7 PCR Expenditure and Budgets

7.1 This Chapter
7.2 Current Financial budget
7.3 Future Expenditure
7.4 Future General Budget
Figure 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Table 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Figure 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Table 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Figure 7.3 Cost per sample for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Table 7.3 Cost per sample for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Figure 7.4 The anticipated future breakdown of financial budgets (over the next three years, 2013 To 2016) for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Table 7.4 The anticipated future breakdown of financial budgets (over the next three years, 2013 To 2016) for PCR studies, indicated by individuals who participated in PCR 2013 CLIN

Chapter 8 Purpose of PCR Use

8.1 This Chapter
8.2 Purpose
8.3 Discussion
Figure 8.1 Top ten reasons for using PCR in the biotechnology industry, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.2 Top ten reasons for using PCR in clinics or hospitals, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.3 Top ten reasons for using PCR in hospitals, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.4 Top ten reasons for using PCR in the healthcare industry, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.5 Top ten reasons for using PCR in the pharmaceutical industry, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.6 Top ten reasons for using PCR in research institutes, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.7 Top ten reasons for using PCR in universities, indicated by individuals who participated in PCR 2013 CLIN

Chapter 9 Samples

9.1 This Chapter
9.2 Samples
9.3 Discussion
Figure 9.1 Top ten sample types analysed using PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 9.1 Sample types analysed using PCR, indicated by individuals who participated in PCR 2013 CLIN

Chapter 10 Sample Preparation

10.1 This Chapter
10.2 Sample Preparation
10.3 Discussion
Figure 10.1 Top sample preparation methods of PCR users who participated in PCR 2013 CLIN
Table 10.1 Sample preparation methods of PCR users who participated in PCR 2013 CLIN
Figure 10.2 Other sample preparation methods of PCR users who participated in PCR 2013 CLIN
Table 10.2 Other sample preparation methods of PCR users who participated in PCR 2013 CLIN

Chapter 11 Therapeutic Areas

11.1 This Chapter
11.2 Therapeutic Areas
11.3 Discussion
Figure 11.1 Top ten therapeutic areas of PCR users who participated in PCR 2013 CLIN
Table 11.1 Therapeutic areas of PCR users who participated in PCR 2013 CLIN
Figure 11.2 Other therapeutic areas of PCR users who participated in PCR 2013 CLIN
Table 11.2 Other therapeutic areas of PCR users who participated in PCR 2013 CLIN

Chapter 12 Disease Biomarkers

12.1 This Chapter
12.2 Use of PCR
12.3 Biomarker Types
12.4 Clinical Utility
12.5 Discussion
Figure 12.1 The use of PCR for the study of disease biomarkers, indicated by individuals who participated in PCR 2013 CLIN
Figure 12.2 Principal disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 12.1 Other disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN
Figure 12.3 Clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 12.2 Other clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN

Chapter 13 Bioinformatics Software

13.1 This Chapter
13.2 Bioinformatics Software
13.3 Discussion
Figure 13.1 Top ten bioinformatics software system used for PCR, indicated by users who participated in PCR 2013 CLIN
Table 13.1 Bioinformatics software system used for DNA PCR, indicated by users who participated in PCR 2013 CLIN
Figure 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2013 CLIN
Table 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2013 CLIN

Chapter 14 Innovation

14.1 This Chapter
14.2 Required Innovation
14.3 Recent Innovation
14.4 Future Innovation
14.5 Discussion
Figure 14.1 Top ten most required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 14.1 Most required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
Figure 14.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 14.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
Figure 14.3 Top ten recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 14.3 Recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN
Figure 14.4 Top ten future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 14.4 Future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN

Chapter 15 Quality Control

15.1 This Chapter
15.2 Quality Control
15.3 Future Innovation
15.4 Discussion
Figure 15.1 Top ten most commonly used quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2013 CLIN
Table 15.1 Quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2013 CLIN

Chapter 16 PCR Consumables

Chapter 17 Discussion

Chapter 18 Appendices